Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo

被引:107
作者
Viggeswarapu, M [1 ]
Boden, SD
Liu, YS
Hair, GA
Louis-Ugbo, J
Murakami, H
Kim, HS
Mayr, MT
Hutton, WC
Titus, L
机构
[1] Emory Univ, Sch Med, Emory Spine Ctr, Dept Orthopaed Surg, Atlanta, GA 30322 USA
[2] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA
关键词
D O I
10.2106/00004623-200103000-00008
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: The LIM mineralization protein-1 (LMP-1) gene encodes for an intracellular protein that induces the expression of several bone growth factors. The purpose of the present study was to determine the feasibility and the optimal dose of adenoviral delivery of the LMP-1 cDNA to promote spinal fusion. Methods: A replication-deficient human recombinant adenovirus was constructed with the LMP-1 cDNA driven by a cytomegalovirus promoter. In phase 1, an in vitro dose-response experiment was performed to determine the optimal adenovirus-LMP-1 (AdLMP-1) concentration and infection time. In phase 2, nine rabbits had a single-level posterolateral arthrodesis of the lumbar spine with implantation of a carrier matrix loaded with bone-marrow-derived buffy-coat cells that had been infected for ten minutes with adenovirus containing the cDNA for LMP-1 (AdLMP-1) or beta -galactosidase (AdBgal). In phase 3, posterolateral arthrodesis of the spine was performed with implantation of cells infected with AdLMP-1 (ten rabbits) or cells infected with an empty adenovirus that did not contain LMP-1 cDNA (ten rabbits) and the results were compared. In this phase, peripheral-blood-derived buffy-coat cells were used instead of bone-marrow-derived cells and a collagen-ceramic-composite sponge was used as the carrier. Results: In phase 1, the in vitro dose-response experiment showed that a multiplicity of infection of 0.25 plaque-forming units per cell was the most efficient dose. In phase 2, the implants that had received cells infected with AdLMP-1 induced a solid, continuous spinal fusion mass at five weeks. In contrast, the implants that had received cells infected with AdBgal or a lower dose of AdLMP-1 induced little or no bone formation. In phase 3, a solid spinal fusion was observed at four weeks in all ten rabbits that had received cells infected with AdLMP-1 and in none of the ten rabbits that had received cells infected with the empty adenovirus. Biomechanical and histological testing of the AdLMP-1-treated specimens revealed findings that were consistent with a high-quality spinal fusion. Conclusions: Adenoviral delivery of LMP-1 cDNA promotes spinal fusion in immune-competent rabbits. Clinical Relevance: The use of delivery cells that are readily available from peripheral blood and the short infection time should allow this technique to be performed in any operating room. The use of an ex vivo gene-transfer protocol with a very low dose of virus should minimize the immune response and toxicity seen in association with other adenoviral applications.
引用
收藏
页码:364 / 376
页数:13
相关论文
共 32 条
[1]   Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy [J].
Alden, TD ;
Pittman, DD ;
Beres, EJ ;
Hankins, GR ;
Kallmes, DF ;
Wisotsky, BM ;
Kerns, KM ;
Helm, GA .
JOURNAL OF NEUROSURGERY, 1999, 90 (01) :109-114
[2]  
ALDEN TD, 1998, NEUROSURG FORUM, V4, P12
[3]   Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate [J].
Boden, SD ;
Martin, GJ ;
Morone, MA ;
Ugbo, JL ;
Moskovitz, PA .
SPINE, 1999, 24 (12) :1179-1185
[4]   Differential effects and glucocorticoid potentiation of bone morphogenetic protein action during rat osteoblast differentiation in vitro [J].
Boden, SD ;
McCuaig, K ;
Hair, G ;
Racine, M ;
Titus, L ;
Wozney, JM ;
Nanes, MS .
ENDOCRINOLOGY, 1996, 137 (08) :3401-3407
[5]   1998 Volvo Award winner in basic science studies - Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1) [J].
Boden, SD ;
Titus, L ;
Hair, G ;
Liu, YS ;
Viggeswarapu, M ;
Nanes, MS ;
Baranowski, C .
SPINE, 1998, 23 (23) :2486-2492
[6]   LMP-1, a LIM-domain protein, mediates BMP-6 effects on bone formation [J].
Boden, SD ;
Liu, YS ;
Hair, GA ;
Helms, JA ;
Hu, D ;
Racine, M ;
Nanes, MS ;
Titus, L .
ENDOCRINOLOGY, 1998, 139 (12) :5125-5134
[7]   AN EXPERIMENTAL LUMBAR INTERTRANSVERSE PROCESS SPINAL-FUSION MODEL - RADIOGRAPHIC, HISTOLOGIC, AND BIOMECHANICAL HEALING CHARACTERISTICS [J].
BODEN, SD ;
SCHIMANDLE, JH ;
HUTTON, WC .
SPINE, 1995, 20 (04) :412-420
[8]   The use of coralline hydroxyapatite with bone marrow, autogenous bone graft, or osteoinductive bone protein extract for posterolateral lumbar spine fusion [J].
Boden, SD ;
Martin, GJ ;
Morone, M ;
Ugbo, JL ;
Titus, L ;
Hutton, WC .
SPINE, 1999, 24 (04) :320-327
[9]  
Boden SD, 1997, J SPINAL DISORD, V10, P1
[10]  
BODEN SD, 1995, J BONE JOINT SURG AM, V77, P1404, DOI 10.2106/00004623-199509000-00017